Status of Parathyroid Hormone in Maintenance Hemodialysis Patients

Abstract

Background: Numerous negative outcomes of Chronic Kidney Disease (CKD) receiving maintenance haemodialysis (MHD) are linked to secondary hyperparathyroidism (SPTH), hypocalcaemia and hyperphosphataemia. Its management is difficult for these patients. Currently, appropriate haemodialysis (HD) is maintained, and parathyroid hormone (PTH) is reduced with vitamin D receptor analogs (VDRA) and/or calcimimetics or parathyroidectomy. Objective: The main objective of this study was to evaluate the status of parathyroid hormone in maintenance Hemodialysis patients in Bangladesh. Method: This observational study was conducted in the haemodialysis unit of National Institute of Kidney Disease and Urology (NIKDU) and Bangladesh Institute of Research & Rehabilitation on Diabetes, Endocrine and Metabolism (BIRDEM). Patients getting maintenance haemodialysis in NIKDU and BIRDEM were enrolled in this study. Results: The mean age of the patients was 50.4±13.13 years. Male female ratio was 1.3:1. The mean BMI was 23.5±4.7 kg/m2 with range from 15.6 to 45.5 kg/m2. 114(95.0%) patients had HTN and 56(46.7%) patients had DM. The duration of haemodialysis was 25.55±25.0 months and 71 (59.2%) patients had twice haemodialysis session/weeks. Mean duration on hemodialysis was 23 ± 19 months (Range 2-124). Conclusion: The majority of our hemodialysis patients weren't dialyzed properly.